At some point in early 2026, Eli Lilly became the most polarizing stock in the pharmaceutical world. Too expensive for value investors. Too dominant to ignore for growth investors. The result: a lot of people watching from the sidelines while the business kept printing records.
Here’s where things stand right now. Lilly trades near $948 — down about 9% year to date from its 52-week high of around $1,132. On one hand, a pullback from a peak. On the other hand, the business just reported its strongest quarter in company history.
Q1 2026 revenue came in at $19.8 billion, up 56% year over year. Net income rose 168%. Non-GAAP EPS of $8.55 beat Wall Street’s estimate of $6.85 by nearly 25%. Management not only met expectations — they raised full-year revenue guidance to a range of $82 billion to $85 billion after just one quarter.
That raised guidance is important. It suggests this isn’t a one-quarter beat. It’s a trajectory call.
The Drug Running Everything
Mounjaro delivered $8.66 billion in Q1 alone, overtaking Merck’s Keytruda as the world’s top-selling drug. That’s not a GLP-1 story anymore. That’s a pharmaceutical dominance story. Mounjaro’s Q1 sales were up 125% year over year. Its obesity-specific twin, Zepbound, grew 80% in the same period.
To be fair, Novo Nordisk got to market first. Wegovy had first-mover advantage and brand recognition. But when Novo faced production issues and Eli Lilly’s tirzepatide-based injections proved more clinically effective, the market shifted. What was a close race two years ago has widened into a meaningful lead.
The GLP-1 pill chapter is just beginning. Lilly’s FDA-approved oral GLP-1, Foundayo, received approval earlier in 2026 as the only approved GLP-1 pill that can be taken any time of day, without food and water restrictions. Early uptake has been sluggish — management has been transparent about that — but the structural opportunity is significant. An oral option removes one of the biggest adoption barriers for patients who won’t self-inject.
Novo Nordisk launched their own Wegovy pill earlier this year and surpassed 3 million prescriptions in just over five months. That validates the oral market is real. The question is who captures more of it as awareness grows.
This Isn’t a One-Drug Company Anymore
What’s interesting is how Lilly is deploying its GLP-1 cash flows. The company is actively reinvesting in a pipeline that now extends well beyond obesity. Q1 included pipeline progress across all four of Lilly’s therapeutic areas — including Alzheimer’s drug Kisunla, where the company is presenting 16 abstracts at the major Alzheimer’s Association conference in London this week.
The AI angle inside Lilly is underappreciated too. The company has built out a broader TuneLab platform aimed at accelerating pipeline development through AI-assisted research. Whether that translates into meaningful time-to-market advantages is unproven at scale, but the infrastructure investment is real and the ambition is clear.
Starting this week, eligible seniors on Medicare can also access GLP-1 drugs for obesity with a $50/month copay through a temporary bridge program. That’s a potential volume unlock for a patient population that had largely been priced out. Analysts are watching whether prescription velocity accelerates from here going into Q2 results, scheduled for August 5.
The Valuation Question
The honest answer is: Lilly is not cheap. Trading at roughly 35 times forward earnings, there’s not a lot of margin for disappointment. If GLP-1 pricing pressure deepens beyond current levels, or if pharma tariffs materialize in the second half of 2026, the multiple compression math gets uncomfortable fast.
That said, the stock has lagged earnings growth significantly. Over the last three years, EPS has grown roughly 56% annually while the share price rose about 31% per year. The earnings have been outrunning the stock. That gap doesn’t close immediately, but it’s not the typical picture of an expensive growth name where valuation has gotten ahead of results.
Gross margins sit at 82.6%. The company’s five-year return is over 400%. The consensus price target among 30 analysts sits around $1,240 — roughly 30% above where the stock trades today.
What to Watch
August 5 is the next major inflection point. Q2 results will tell investors whether Foundayo is gaining prescription traction, whether Mounjaro pricing is holding, and whether Lilly’s raised full-year guidance turns out to be conservative or optimistic. The retatrutide pipeline candidate — which produced the most dramatic weight loss numbers seen yet in any clinical trial — is also progressing toward later-stage data.
This is a rare combination: a stock that’s pulled back from its high, backed by a business delivering record revenue, record earnings, and a raised outlook. That gap between price and momentum doesn’t stay open indefinitely.
The Q2 report on August 5 will be worth watching closely.
This article is for informational purposes only and does not constitute investment advice. All investments involve risk, including the possible loss of principal. Past performance is not indicative of future results. Please consult a qualified financial advisor before making any investment decisions.
